People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neogene Therapeutics, Inc. | — | Biotechnology | Series D+ | $125.0M | $4.3B | 2019 |
Antonius N.M. Schumacher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Antonius N.M. Schumacher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David M. Tanen | 1 | 8 |
| Katherine Wood | 1 | 3 |
| Rajul Jain | 1 | 3 |
| David Tanen | 1 | 1 |
| Caroline N.M. Stout | 1 | 1 |
| Franz N.M. Humer | 1 | 1 |
| Elisa N.M. Petris | 1 | 1 |
| Fei M. Chen | 1 | 1 |
| Helen M. Kim | 1 | 1 |
| Rachel N.M. Mears | 1 | 1 |
| Carsten Linnemann, PhD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.